- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||fezakinumab|
|Search PubMed titles||fezakinumab|
|Search PubMed titles/abstracts||fezakinumab|
|Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab .